Homepage Top Section1

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies. Under the deal, Novartis gets the sole rights

The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to

With the distribution agreement, Ocugen will have the rights to the vaccine candidate in the US and will also be accountable for clinical development, regulatory approval and commercialisation

The study was led by Torri Metz of University of Utah Health and Rebecca Clifton of George Washington University’s Milken Institute School of Public Health. When compared to

As per the agreement, Sanofi will manufacture 125 million doses of the Covid-19 vaccine in Europe. Initial supplies of vaccine are expected to come out of Sanofi’s facilities

BIO 300 is Humanetics’ drug candidate which is expected to counteract and relieve not only severe and chronic inflammatory diseases but also radiation toxicities. The progressive pulmonary inflammation

As part of the development, Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have signed an agreement to

Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified

According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3